A. Beeghly

发表

IGF-II promoter methylation and ovarian cancer prognosis

D. Katsaros, T. Rutherford, H. Yu, 2007, Journal of Cancer Research and Clinical Oncology.

Integrating transcription factor occupancy with transcriptome-wide association analysis identifies susceptibility genes in human cancers

X. Shu, W. Zheng, W. Wen, 2022, Nature Communications.

African‐American/White differences in breast carcinoma

C. Howe, S. Kasl, F. Duan, 2004, Cancer.

Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation.

A. Joyner, C. Hui, M. Matise, 2000, Development.

Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential

D. Katsaros, D. Zelterman, R. Singal, 2006, Cancer.

Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

D. Katsaros, H. Risch, M. Massobrio, 2006, Gynecologic oncology.

Mouse Gli 1 mutants are viable but have defects in SHH signaling in combination with a Gli 2 mutation

A. Joyner, C. Hui, M. Matise, 2000 .

Toward the construction of integrated physical and genetic maps of the mouse genome using interspersed repetitive sequence PCR (IRS-PCR) genomics.

D. Housman, H. Lehrach, L. Schalkwyk, 1996, Genome research.

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

I. Puzanov, G. Schwartz, W. Tap, 2022, Cancers.

Racial Differences in the Association of Endometriosis and Uterine Leiomyomas With the Risk of Ovarian Cancer

A. Wu, E. Myers, J. Schildkraut, 2023, Obstetrics and gynecology.

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Y. Shyr, P. Razavi, E. Ruíz-García, 2023, JAMA oncology.